ITF Therapeutics: Givinostat Efficacy & Safety in Duchenne MD
Okay, here’s teh extracted information from the provided text, focusing on the email address and the list of references:
Email Address:
[email protected]
References:
- Sandonà M, Cavioli G, Renzini A, et al. Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies. Int J Mol Sci. 2023;24(5):4306. https://doi.org/10.3390/ijms24054306
- consalvi S, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL. Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic drugs for Genetic diseases. Mol Med. 2011;17(5):457-465. https://doi.org/10.2119/molmed.2011.00049
- Bez Batti Angulski A, Hosny N, Cohen H, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol. 2023;14:1183101. https://doi.org/10.3389/fphys.2023.1183101
- Giuliani G, Rosina M, Reggio A. Signaling pathways regulating the fate of fibro/adipogenic progenitors (FAPs) in skeletal muscle regeneration and disease. FEBS J. 2022;289(21):6484-6517.https://doi.org/10.1111/febs.16080
- Walter MC, Reilich P. Recent developments in Duchenne muscular dystrophy: facts and numbers. J Cachexia Sarcopenia Muscle. 2017;8(5):681-685.https://doi.org/10.1002/jcsm.12245
- Crisafulli S, Sultana J (The reference is incomplete in the provided text).
Let me know if you’d like me to do anything else with this information! Such as, I could format it differently, or try to find the complete 6th reference if you provide more text.